Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer
BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771099/ https://www.ncbi.nlm.nih.gov/pubmed/26918265 http://dx.doi.org/10.12659/MSM.897330 |
_version_ | 1782418365103472640 |
---|---|
author | Sun, Ling Chen, Yifan Su, Qiaoli Tang, Xiaoju Liang, Yasha Che, Guowei Luo, Fengming |
author_facet | Sun, Ling Chen, Yifan Su, Qiaoli Tang, Xiaoju Liang, Yasha Che, Guowei Luo, Fengming |
author_sort | Sun, Ling |
collection | PubMed |
description | BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. RESULTS: Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. CONCLUSIONS: All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis. |
format | Online Article Text |
id | pubmed-4771099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-47710992016-03-14 Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer Sun, Ling Chen, Yifan Su, Qiaoli Tang, Xiaoju Liang, Yasha Che, Guowei Luo, Fengming Med Sci Monit Clinical Research BACKGROUND: MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors. MATERIAL/METHODS: This study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method. RESULTS: Plasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only. CONCLUSIONS: All these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis. International Scientific Literature, Inc. 2016-02-26 /pmc/articles/PMC4771099/ /pubmed/26918265 http://dx.doi.org/10.12659/MSM.897330 Text en © Med Sci Monit, 2016 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Clinical Research Sun, Ling Chen, Yifan Su, Qiaoli Tang, Xiaoju Liang, Yasha Che, Guowei Luo, Fengming Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title | Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title_full | Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title_fullStr | Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title_full_unstemmed | Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title_short | Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer |
title_sort | increased plasma mirna-30a as a biomarker for non-small cell lung cancer |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771099/ https://www.ncbi.nlm.nih.gov/pubmed/26918265 http://dx.doi.org/10.12659/MSM.897330 |
work_keys_str_mv | AT sunling increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT chenyifan increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT suqiaoli increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT tangxiaoju increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT liangyasha increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT cheguowei increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer AT luofengming increasedplasmamirna30aasabiomarkerfornonsmallcelllungcancer |